Study of Gecacitinib Tablets Combined With Pegylated Interferon as First Treatment for Adults With Polycythemia Vera

What this Trial Is About

Researchers are evaluating the combination of Gecacitinib Hydrochloride Tablets and pegylated interferon alfa-2b as a first-line treatment for adults with polycythemia vera PV. This study aims to determine if patients can achieve hematological remission after 24 weeks of this combined therapy, focusing on both the effectiveness and safety of the treatment. Participants will receive Gecacitinib orally at a dose of 100 mg twice daily on an empty stomach, along with a weekly subcutaneous injection of 90 micrograms of pegylated interferon alfa-2b, administered in the abdomen or thigh. The treatment period lasts for 24 weeks, during which patients will visit the hospital regularly for examinations and follow-up assessments. During the trial, participants will undergo various evaluations including blood tests, spleen size assessments, symptom improvement checks, and monitoring of the JAK2 mutation burden at weeks 4, 12, and 24. The primary outcome is the hematologic remission rate at week 24. Safety and treatment adherence will be monitored throughout the study, with the entire participation lasting about 24 weeks.

A Clinical Study of Gecacitinib Combined With Pegylated Interferon in Patients With PV